GRETCHEN GENATO: Open Payments
NPI 1245603174 · SANTA MONICA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,521 in 33 payments from 13 companies in 2025. Trend: 2023 $1,271 · 2024 $1,303 · 2025 $1,521
Food & beverage: $1,521
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $254 |
| Teva Pharmaceuticals USA, Inc. | 2 | $235 |
| Janssen Pharmaceuticals, Inc | 3 | $182 |
| Vanda Pharmaceuticals Inc. | 6 | $179 |
| Alkermes, Inc. | 3 | $149 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $125 |
| ABBVIE INC. | 5 | $121 |
| E.R. Squibb & Sons, L.L.C. | 1 | $119 |
| Bausch Health US, LLC | 3 | $71 |
| Axsome Therapeutics, Inc. | 1 | $35 |
Products named: CAPLYTA, SPRAVATO, FANAPT, ARISTADA, LUMRYZ, VRAYLAR, UZEDY, COBENFY.
Industry payments across CA — which companies pay providers there.
